Results 1 to 10 of about 2,000 (98)

Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination. [PDF]

NPJ Vaccines, 2023
Gardasil® (Merck) and Cervarix® (GlaxoSmithKline) both provide protection against infection with Human Papillomavirus 16 (HPV16) and Human Papillomavirus 18 (HPV18), that account for around 70% of cervical cancers. Both vaccines have been shown to induce
Roy V, Jung W, Linde C, Coates E, Ledgerwood J, Costner P, Yamshchikov G, Streeck H, Juelg B, Lauffenburger DA, Alter G.   +10 more
europepmc   +2 more sources

Impact of HPV vaccination with Gardasil® in Switzerland. [PDF]

BMC Infect Dis, 2017
Background Gardasil®, a quadrivalent vaccine targeting low-risk (6, 11) and high-risk (16, 18) human papillomaviruses (HPV), has been offered to 11–14 year-old schoolgirls in Switzerland since 2008.
Jacot-Guillarmod M, Pasquier J, Greub G, Bongiovanni M, Achtari C, Sahli R.   +5 more
europepmc   +2 more sources

Evaluation of the thermal stability and the protective efficacy of spray-dried HPV vaccine, Gardasil® 9. [PDF]

Hum Vaccin Immunother, 2019
High-risk human papillomavirus (HPV) types are responsible for nearly all cases of cervical cancers. Cervarix® and Gardasil® 9 are the current prophylactic vaccines available that protect against the majority of HPVs associated with cancer.
Kunda NK, Peabody J, Zhai L, Price DN, Chackerian B, Tumban E, Muttil P.   +6 more
europepmc   +2 more sources

Gardasil^® as adjunctive therapy for respiratory papillomatosis at Red Cross Children's Hospital, Cape Town. [PDF]

J Coll Med S Afr
Background: Juvenile onset recurrent respiratory papillomatosis (JoRRP) is an incurable condition caused by human papilloma virus (HPV) types 6 and 11, often requiring repeated surgeries and in severe cases, tracheostomy.
Frank S, McGuire JK, Kabagenyi F, Peer S.   +3 more
europepmc   +2 more sources

Real-world safety of HPV vaccines over 18 y: A comprehensive analysis of U.S. VAERS reports. [PDF]

Hum Vaccin Immunother
Human papillomavirus (HPV) vaccination is central to preventing cervical and other HPV-associated cancers. Although clinical trials have established favorable safety profiles, long-term, brand-specific real-world data remain limited. We evaluated adverse
Su Y, Huang Y, Wei J, Wang X, Zhou Y, Wu X, Fu H.   +6 more
europepmc   +2 more sources

A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls. [PDF]

PLoS One, 2013
The current generation of Human Papillomavirus (HPV) vaccines, Cervarix® and Gardasil®, exhibit a high degree of efficacy in clinical trials against the two high-risk (HR) genotypes represented in the vaccines (HPV16 and HPV18).
Draper E, Bissett SL, Howell-Jones R, Waight P, Soldan K, Jit M, Andrews N, Miller E, Beddows S.   +8 more
europepmc   +2 more sources

Immunogenicity of an <i>Escherichia coli</i>-Produced Recombinant 9-Valent Human Papillomavirus Vaccine in Mice and Rats. [PDF]

Vaccines (Basel)
Background: Prophylactic human papillomavirus (HPV) vaccines are crucial for preventing HPV-related cancers. This study aimed to preclinically evaluate a novel recombinant 9-valent HPV vaccine produced in Escherichia coli (E.
Liu YY, Yin F, Li WJ, Chen D, Wu SM, Chen X, Wang Y, Yang ZM, Zhang HJ, Liu YJ.   +9 more
europepmc   +2 more sources

Immunogenicity of one and two doses of Gardasil®9 in Tanzanian girls in the DoRIS Trial. [PDF]

NPJ Vaccines
Tanzanian girls received one to three doses of Gardasil®9 in the DoRIS randomised trial. Blood samples from one and two-dose Gardasil®9 recipients were collected at months (M)0, M7, M12, M24, and M36 for testing via an HPV Multiplex immunoassay.
Kemp TJ, Baisley K, Changalucha J, Indangasi J, Whitworth H, Lacey CJ, Mwanzalima D, Hashim R, Kapiga S, Hayes RJ, Pinto LA, Watson-Jones D.   +11 more
europepmc   +2 more sources

An engineered intradermal microneedle-array device enhances the cellular immune responses in a guinea pig model. [PDF]

Front Immunol
IntroductionIntradermal (ID) vaccination can be highly immunogenic due to the density of antigen-presenting cells in the skin, but reliable ID delivery remains technically challenging.
Nepveu-Traversy ME, Babuadze GG, Potterton D, de La Vega MA, Alajbegovic A, Julien J, Winterborn A, Kobinger G.   +7 more
europepmc   +2 more sources

Therapeutic Impact of Gardasil^® in Recurrent Respiratory Papillomatosis: A Retrospective Study on RRP Patients. [PDF]

Viruses
Background: Recurrent respiratory papillomatosis (RRP) is a rare, non-malignant disease caused by human papillomavirus (HPV) types 6 and 11. The condition primarily affects the larynx, potentially leading to life-threatening airway obstruction.
Sieg J, Fazel A, Quabius ES, Dempfle A, Wiegand S, Hoffmann M.   +5 more
europepmc   +2 more sources